The DOI matches its Crossref record.
Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population
Open accessAbstract
The B-type Raf kinase (BRAF) protein is a serine/threonine kinase that has an important role in cellular proliferation, differentiation, and programmed cell death. The BRAF gene has been recently found to be mutated in human carcinomas, predominantly in malignant melanoma. The aim of this study was to investigate the frequency of the BRAF mutation in papillary thyroid carcinoma (PTC) of Koreans through direct DNA sequencing of the polymerase chain reaction (PCR)- amplified exon 15 with clinicopathological features. Seventy paraffin-embedded conventional papillary carcinomas in the thyroid gland were evaluated. The BRAF missense mutation at V599E was found in 58 of 70 PTCs (83%). The frequency of our series was much higher than the frequencies of other PTC series (36 - 69%). The frequency of nodal metastasis was also significantly higher in the BRAF mutation group (p= 0.048). These results suggest that the BRAF mutation is involved in the carcinogenesis in most conventional PTCs, especially those occurring in Koreans, and this is a potentially valuable marker for the evaluation of prognosis of patients with PTC. These findings support the specific inhibitors of BRAF being promising targets for the disease outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
Xing, M. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0007 · Cited by 983
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Gupta-Abramson, V., Troxel, A. B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S. J., Flaherty, K. T., Loevner, L. A., O'Dwyer, P. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3279 · Cited by 680
Update on Fundamental Mechanisms of Thyroid Cancer
Prete, A., Borges de Souza, P., Censi, S., Muzza, M., Nucci, N., & Sponziello, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00102 · Cited by 471
Knauf, J. A., Ma, X., Smith, E. P., Zhang, L., Mitsutake, N., Liao, X.-H., Refetoff, S., Nikiforov, Y. E., & Fagin, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0047 · Cited by 414
Tufano, R. P., Teixeira, G. V., Bishop, J., Carson, K. A., & Xing, M. (2012) · Medicine · doi:10.1097/md.0b013e31826a9c71 · Cited by 302
Lee, J., Lee, E., & Kim, Y. (2007) · Cancer · doi:10.1002/cncr.22754 · Cited by 291
ITO, Y., YOSHIDA, H., MARUO, R., MORITA, S., TAKANO, T., HIROKAWA, M., YABUTA, T., FUKUSHIMA, M., INOUE, H., TOMODA, C., et al. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-208 · Cited by 255
Trovisco, V., Soares, P., Preto, A., de Castro, I. V., Lima, J., Castro, P., Máximo, V., Botelho, T., Moreira, S., Meireles, A. M., et al. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1236-0 · Cited by 253
Clinicopathological relevance of BRAF mutations in human cancer
Pakneshan, S., Salajegheh, A., Anthony Smith, R., & King-Yin Lam, A. (2013) · Pathology · doi:10.1097/pat.0b013e328360b61d · Cited by 156
New molecular targeted therapies in thyroid cancer
Milano, A., Chiofalo, M. G., Basile, M., Salzano de Luna, A., Pezzullo, L., & Caponigro, F. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000224449.16329.c5 · Cited by 26
Genetic mutations, molecular markers and future directions in research
Patel, K. N. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.03.437 · Cited by 6
Metadata
- Authors
- Kim, K. H., Kang, D. W., Kim, S. H., Seong, I. O., & Kang, D. Y.
- Venue
- Yonsei Medical Journal
- Published
- 2004
- Volume
- 45
- Issue
- 5
- Pages
- 818
- ISSN
- 0513-5796 (ISSN-L)
- OpenAlex
- W2030067547
- Cited by
- 229
- References
- 0
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.